language_icon
EN
HI

Thyrocare Technologies Share price

THYROCARE

395.35

7.85 (2.03%)
NSE
BSE
Last updated on 22 Apr, 2026 | 15:05 IST
Today's High

396.20

Today's Low

385.05

52 Week Low

234.33

52 Week High

536.67

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Thyrocare Technologies Chart

Thyrocare Technologies Share Key Metrics

Volume
1.47 L
Market Cap
6167.66 CR
LTQ@LTP
2@395.35
ATP
392.43
Var Margin
35 %
Circuit Range
310-465
Delivery %
69.54 %
Value
5.78 CR
ASM/GSM
No
Market Lot
1

Summary

Thyrocare Technologies share price stands at ₹395.35 at 22 Apr, 2026 | 15:05. The stock Thyrocare Technologies intraday movement has stayed between ₹385.05 and ₹396.20, while on a 52-week basis it has fluctuated from ₹234.33 to ₹536.67.
In terms of trading activity, Thyrocare Technologies has recorded a volume of 147285 shares. The Thyrocare Technologies has a market cap of ₹159165315. The stock’s Average Traded Price (ATP) stands at ₹39243, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 2, 39535.
The Thyrocare Technologies operates within a circuit range of ₹310-465 – ₹310-465, with a Value of ₹5.78 CR. The Delivery Percentage for the day is 69.54%. Additionally, Thyrocare Technologies currently falls under the No framework, and trades with a market lot size of 1.

Thyrocare Technologies Fundamentals

View More
P/E Ratio

45.4

P/B Ratio

9.35

Div. Yield

1.78

Sector P/E

52.87

Sector P/B

-16.29

Sec. Div. Yield

2.27

Thyrocare Technologies Resistance and Support

Pivot 390.87

Resistance

First Resistance

395.04

Second Resistance

402.57

Third Resistance

406.74

Support

First Support

383.34

Second Support

379.17

Third Support

371.64

Thyrocare Technologies Shareholding Pattern

View More
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

60.92%

Mutual Fund

19.45%

Insurance

0.37%

Foreign Institutional Investors

5.37%

Domestic Institutional Investors

1.17%

Retail

12.71%

Others

0.01%

Total Promoters
MAR '26
60.92%

Thyrocare Technologies Corporate Actions

DateAgenda
2026-01-28Quarterly Results
2025-10-14Qtr Results
2025-07-23Quarterly Results
2025-04-23Audited Results & Final Dividend
2025-01-23Quarterly Results

Thyrocare Technologies News

Thyrocare Technologies Limited

Thyrocare insiders, Geetanjali Satish Shahane and Priyanka Jagnani Jain, acquired 3,500 equity shares for ₹12.34 lakhs through market purchase on March 30, 2026. These transactions were executed on the NSE.
Apr 01 2026 19:04:00

Thyrocare Technologies Ltd - 539871 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

Docon Technologies promoter API Holdings partially redeemed Series 1 Non-Convertible Debentures aggregating ₹120 crore on March 30, 2026. This action reduced the face value per debenture from ₹10 lakh to ₹9 lakh, while maintaining the same number of encumbered Thyrocare shares.
Apr 01 2026 10:04:00

Thyrocare Technologies Limited

Thyrocare Technologies received a notice of demand from the Income Tax Department for ₹2.02 crore relating to Assessment Year 2024-25. The company plans to contest this demand and states it has no material financial or operational impact.
Mar 29 2026 20:03:00
Read More

About Thyrocare Technologies

NSE : 17032  
BSE : 539871  
ISIN : INE594H01019  

The Company was incorporated as Thyrocare Technologies Limited on January 28 2000 at Mumbai as a public limited company under the Companies Act 1956. the Company was issued a certificate of commencement of business from the RoC on March 7 2000. Major events and milestones of the Company :2000-The Company was incorporated in the name and style of "Thyrocare Technologies Limited? and received a certificate for commencement of operations. 2001-The Company received ISO 9001 certification. -The Company commenced commercial operations under the brand name 'Thyrocare' pursuant to the acquisition of business of TDPL and TBPL (which were incorporated in 1996). 2005-The Company received NABL accreditation. 2006-The Company issued certain fully convertible debentures aggregating to 250 million to BCCL. 2007-The Company receives accreditation from the College of American Pathologists (CAP). 2010-The Company issued certain compulsorily convertible debentures aggregating to 250 million to Agalia. Agalia also acquired certain Equity Shares aggregating to 1250 million from the Promoters and certain other persons. -The Company launched wellness packages under the brand name "Aarogyam". 2011-The Company migrated to "total laboratory automation system" installed by Siemens for efficient handling of increasing volumes. 2012-NVP acquired certain Equity Shares aggregating to 1200 million from certain entities. 2013-EIF acquired certain Equity Shares from Agalia. -The Subsidiary commenced operations at the PET-CT centres at Navi Mumbai and conducted over 1000 scans in the first year of operation. 2014-The Company had installed India?s first and the world?s longest track automation system for seamless sample movements from Siemens Limited. -The Company commissioned the operations in medical cyclotron facility in Navi Mumbai. -The Subsidiary commenced operations at the PET-CT centres in New Delhi and Hyderabad and the PET-CT centres at New Delhi conducted over 1000 scans in the first year of operations. 2015-The Company opened RPLs in Delhi Coimbatore Hyderabad and Kolkata to expand its coverage and volume of tests and samples processed daily. -The Company acquired the equipment for testing of water samples and commenced operating the equipment under the brand name "WHATERS". These tests at present include physical and chemical testing elements testing microbiology testing pesticide testing and volatile organic compounds testing. -The Subsidiary has completed over 10000 scans at the PET-CT centres in New Delhi over 10000 scans at the PET-CT centres in Navi Mumbai from the date of inception and over 1000 scans at the PET-CT centres in Hyderabad since inception.

Read More

Thyrocare Technologies Management

NamePosition
Brijesh KumarCompany Secretary & Compliance Officer
Rahul GuhaManaging Director & Chief Executive Officer
View More

Thyrocare Technologies FAQs

The Buying Price of Thyrocare Technologies share is 395.35 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Thyrocare Technologies stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Thyrocare Technologies, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Thyrocare Technologies shares is 45.4. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Thyrocare Technologies shares is 9.35. Useful to assess the stock's value relative to its book value.

To assess Thyrocare Technologies’s valuation compare Sector P/E, P/B which are 52.87 & -16.29 with sector averages, along with growth rates and financial metrics.

The Market Cap of Thyrocare Technologies is 6167.66 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Thyrocare Technologies share price is 536.67 & 234.33. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Thyrocare Technologies belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost